Definium Therapeutics Inc. Insider Trading

DFTX

Last 12 months

Insiders sold $7M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Dec 2024.

Net open-market

−$7M

0 buys · 17 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Dec 2024

Dec 5, 2024

Get an email when DFTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 25	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	10,853	$36.57	397K	1.4%	Form 4
Sep 25	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	31,550	$36.57	$1.15M	1.4%	Form 4
Sep 25	Matthew T. Wiley Chief Commercial Officer	Sold10b5-1 plan	3,097	$36.57	113K	0.9%	Form 4
Sep 25	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	14,051	$36.57	514K	2.8%	Form 4
Sep 25	Brandi Roberts Chief Financial Officer	Sold10b5-1 plan	3,377	$36.57	123K	0.8%	Form 4
Sep 3	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	19,023	$37.94	722K	1.3%	Form 4
Jun 25	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	13,008	$45.03	586K	3.9%	Form 4
Jun 25	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	10,035	$45.03	452K	2.0%	Form 4
Jun 25	Brandi Roberts Chief Financial Officer	Sold10b5-1 plan	3,013	$45.03	136K	1.4%	Form 4
Jun 25	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	29,208	$45.03	$1.32M	2.6%	Form 4
Jun 25	Matthew T. Wiley Chief Commercial Officer	Sold10b5-1 plan	2,867	$45.03	129K	1.6%	Form 4
Mar 25	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	8,018	$18.47	148K	1.9%	Form 4
Mar 25	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	10,702	$18.47	198K	3.8%	Form 4
Mar 25	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	24,431	$18.47	451K	3.1%	Form 4
Dec 26, 2025	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	5,600	$13.15	74K	1.3%	Form 4
Dec 26, 2025	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	25,791	$13.15	339K	3.2%	Form 4
Dec 26, 2025	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	11,276	$13.15	148K	3.8%	Form 4
Sep 25, 2025	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	11,278	$9.77	110K	3.7%	Form 4
Sep 25, 2025	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	25,797	$9.77	252K	3.1%	Form 4
Sep 25, 2025	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	7,704	$9.77	75K	1.8%	Form 4
Jun 25, 2025	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	11,491	$6.80	78K	3.6%	Form 4
Jun 25, 2025	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	7,848	$6.80	53K	1.8%	Form 4
Jun 25, 2025	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	26,491	$6.80	180K	3.1%	Form 4
Mar 25, 2025	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	21,208	$6.74	143K	2.4%	Form 4
Mar 25, 2025	Daniel Karlin Chief Medical Officer	Sold10b5-1 plan	6,836	$6.74	46K	1.5%	Form 4
Mar 25, 2025	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	6,576	$6.74	44K	2.0%	Form 4
Mar 25, 2025	Carrie Liao Chief Accounting Officer	Sold10b5-1 plan	2,347	$6.74	16K	1.6%	Form 4
Dec 26, 2024	Robert Barrow Chief Executive Officer	Sold10b5-1 plan	19,106	$7.43	142K	3.5%	Form 4
Dec 26, 2024	Carrie Liao Chief Accounting Officer	Sold10b5-1 plan	2,273	$7.43	17K	2.3%	Form 4
Dec 26, 2024	Dan Karlin Chief Medical Officer	Sold10b5-1 plan	6,643	$7.43	49K	1.9%	Form 4
Dec 26, 2024	Mark Sullivan Chief Legal Officer	Sold10b5-1 plan	4,519	$7.43	34K	2.5%	Form 4
Dec 5, 2024	David W Gryska Director	Bought	2,500	$7.17	18K	14%	Form 4

Sep 2510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 10,853 at $36.57
397K
1.4% of stake
Sep 2510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 31,550 at $36.57
$1.15M
1.4% of stake
Sep 2510b5-1 plan
Matthew T. Wiley
Chief Commercial Officer · sold 3,097 at $36.57
113K
0.9% of stake
Sep 2510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 14,051 at $36.57
514K
2.8% of stake
Sep 2510b5-1 plan
Brandi Roberts
Chief Financial Officer · sold 3,377 at $36.57
123K
0.8% of stake
Sep 310b5-1 plan
Robert Barrow
Chief Executive Officer · sold 19,023 at $37.94
722K
1.3% of stake
Jun 2510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 13,008 at $45.03
586K
3.9% of stake
Jun 2510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 10,035 at $45.03
452K
2.0% of stake
Jun 2510b5-1 plan
Brandi Roberts
Chief Financial Officer · sold 3,013 at $45.03
136K
1.4% of stake
Jun 2510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 29,208 at $45.03
$1.32M
2.6% of stake
Jun 2510b5-1 plan
Matthew T. Wiley
Chief Commercial Officer · sold 2,867 at $45.03
129K
1.6% of stake
Mar 2510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 8,018 at $18.47
148K
1.9% of stake
Mar 2510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 10,702 at $18.47
198K
3.8% of stake
Mar 2510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 24,431 at $18.47
451K
3.1% of stake
Dec 26, 202510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 5,600 at $13.15
74K
1.3% of stake
Dec 26, 202510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 25,791 at $13.15
339K
3.2% of stake
Dec 26, 202510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 11,276 at $13.15
148K
3.8% of stake
Sep 25, 202510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 11,278 at $9.77
110K
3.7% of stake
Sep 25, 202510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 25,797 at $9.77
252K
3.1% of stake
Sep 25, 202510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 7,704 at $9.77
75K
1.8% of stake
Jun 25, 202510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 11,491 at $6.80
78K
3.6% of stake
Jun 25, 202510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 7,848 at $6.80
53K
1.8% of stake
Jun 25, 202510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 26,491 at $6.80
180K
3.1% of stake
Mar 25, 202510b5-1 plan
Robert Barrow
Chief Executive Officer · sold 21,208 at $6.74
143K
2.4% of stake
Mar 25, 202510b5-1 plan
Daniel Karlin
Chief Medical Officer · sold 6,836 at $6.74
46K
1.5% of stake
Mar 25, 202510b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 6,576 at $6.74
44K
2.0% of stake
Mar 25, 202510b5-1 plan
Carrie Liao
Chief Accounting Officer · sold 2,347 at $6.74
16K
1.6% of stake
Dec 26, 202410b5-1 plan
Robert Barrow
Chief Executive Officer · sold 19,106 at $7.43
142K
3.5% of stake
Dec 26, 202410b5-1 plan
Carrie Liao
Chief Accounting Officer · sold 2,273 at $7.43
17K
2.3% of stake
Dec 26, 202410b5-1 plan
Dan Karlin
Chief Medical Officer · sold 6,643 at $7.43
49K
1.9% of stake
Dec 26, 202410b5-1 plan
Mark Sullivan
Chief Legal Officer · sold 4,519 at $7.43
34K
2.5% of stake
Dec 5, 2024
David W Gryska
Director · bought 2,500 at $7.17
18K
14% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DFTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biotechnology · Pick stocks to compare with DFTX

CompareIntrinsic value

NEWBRY.XSTONewbury Pharmaceuticals AB

€0.08+15.03%40

HPHA.XETRHeidelberg Pharma AG

€2.01-3.37%10

MEDCL.XPARMedincell SA

€28.68+3.02%40

ZTEKZentek Ltd.

€0.33+0.60%40

XTXXFAdastra Holdings Ltd.

€0.08+0.00%40

XRTXXORTX Therapeutics Inc.

$0.99-1.00%10

VALNValneva SE Sponsored ADR

$5.63+2.18%0

TRIBTrinity Biotech plc Sponsored ADR

$6.43-2.02%10

Held by ETFs

DFTX is in 50 US ETFs. The largest of them, with DFTX's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DFTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.